James Ford

Medical oncologist, GI specialist, Cancer geneticist

Associate Professor of Medicine (Oncology) and of Genetics and, by courtesy, of Pediatrics
Dr. Ford is a medical oncologist and geneticist at Stanford, devoted to studying the genetic basis of breast and GI cancer development, treatment and prevention. Dr. Ford graduated in 1984 Magna Cum Laude (Biology) from Yale University where he later received his M.D. degree from the School of Medicine in 1989. He was a internal medicine resident (1989-91), Clinical Fellow in Medical Oncology (1991-94), Research Fellow of Biological Sciences (1993-97) at Stanford, and joined the faculty in 1998. He is currently Associate Professor of Medicine (Oncology) and Genetics, and Director of the Stanford Cancer Genetics Clinic, at the Stanford University Medical Center.

Dr. Ford’s research goals are to understand the role of genetic changes in cancer genes in the risk and development of common cancers. He studies the role of the p53 and BRCA1 tumor suppressor genes in DNA repair, and uses techniques for high-throughput genomic analyses of cancer to identify molecular signatures for targeted therapies. Recently, his team has identified a novel class of drugs that target DNA repair defective breast cancers, and have opened clinical trials at Stanford and nationally using these “PARP inhibitors” for the treatment of women with “triple-negative” breast cancer.

Dr. Ford’s clinical interests include the diagnosis and treatment of patients with a hereditary pre-disposition to cancer. He runs the Stanford Cancer Genetics Clinic, that sees patients for genetic counseling and testing of hereditary cancer syndromes, and enters patients on clinical research protocols for prevention and early diagnosis of cancer in high-risk individuals.

Cancer Genetics Program

  • 875 Blake Wilbur Drive
  • Palo Alto, CA 94304
  • Phone: 650-498-6000
Learn More About the Clinic Getting Here Make An Appointment

Gastrointestinal (GI) Cancer Program

  • 875 Blake Wilbur Drive
  • Palo Alto, CA 94304
  • Phone: 650-498-6000
Learn More About the Clinic Getting Here Make An Appointment

Professional Education

Medical Education: Yale University School of Medicine (1989) CT

M.D., Yale Medical School, Medicine (1989)

Internship: Stanford University Medical Center (1990) CA

Residency: Stanford University School of Medicine (1991) CA

Fellowship: Stanford University School of Medicine (1994) CA

Board Certification: Medical Oncology, American Board of Internal Medicine (2005)

Honors & Awards

Member, Western Society for Clinical Investigation (2007)

Top Doctor for Cancer, Castle Connolly (2008 -)

Council Chair, California Breast Cancer Research Program (2009 - 10)

Medical Oncology, Best Doctors in America (2013 -)

Administrative Appointments

Director, Stanford Clinical Cancer Genetics Program (2000 - Present)

Director, Oncology Fellowship Training Program (2002 - Present)

Director, Stanford Clinical Cancer Genomics (2013 - Present)

Clinical Trials

Clinical trials are research studies that evaluate a new medical approach, device, drug, or other treatment. As a Stanford Health Care patient, you have access to the latest, advanced clinical trials.

Open trials refer to studies currently accepting participants. Closed trials are not currently enrolling, but may open in the future.

Clinical Evaluation of a Multiple-Gene Sequencing Panel for Hereditary Cancer Risk Assessment
Kurian, A. W., Hare, E. E., Mills, M. A., Kingham, K. E., McPherson, L., & Ford, J. M. (2014). Clinical Evaluation of a Multiple-Gene Sequencing Panel for Hereditary Cancer Risk Assessment. JOURNAL OF CLINICAL ONCOLOGY, 32(19), 2001-2009.

Clinical interpretation and implications of whole-genome sequencing.
Dewey, F. E., Grove, M. E., Pan, C., Goldstein, B. A., Bernstein, J. A., & Quertermous, T. (2014). Clinical interpretation and implications of whole-genome sequencing. JAMA-the journal of the American Medical Association, 311(10), 1035-1045.

Poly (ADP-ribose) polymerase inhibitor LT-626: Sensitivity correlates with MRE11 mutations and synergizes with platinums and irinotecan in colorectal cancer cells
McPherson, L. A., Shen, Y., & Ford, J. M. (2014). Poly (ADP-ribose) polymerase inhibitor LT-626: Sensitivity correlates with MRE11 mutations and synergizes with platinums and irinotecan in colorectal cancer cells. CANCER LETTERS, 343(2), 217-223.

Therapeutic targeting of BRCA1-mutated breast cancers with agents that activate DNA repair.
Alli, E., Solow-Cordero, D., Casey, S. C., & Ford, J. M. (2014). Therapeutic targeting of BRCA1-mutated breast cancers with agents that activate DNA repair. Cancer research.

Metastatic tumor evolution and organoid modeling implicate TGFBR2 as a cancer driver in diffuse gastric cancer.
Nadauld, L. D., Garcia, S., Natsoulis, G., Bell, J. M., Miotke, L., & Ji, H. P. (2014). Metastatic tumor evolution and organoid modeling implicate TGFBR2 as a cancer driver in diffuse gastric cancer. Genome biology, 15(8), 428.

Molecular profiling of gastric cancer: toward personalized cancer medicine.
Nadauld, L. D., & Ford, J. M. (2013). Molecular profiling of gastric cancer: toward personalized cancer medicine. Journal of clinical oncology , 31(7), 838-839.

Lupus Antibody Tops Cancer Cells
Ford, J. M. (2012). Lupus Antibody Tops Cancer Cells. SCIENCE TRANSLATIONAL MEDICINE, 4(157).

Lynch Syndrome in Patients With Colorectal Cancer Finding the Needle in the Haystack
Ladabaum, U., & Ford, J. M. (2012). Lynch Syndrome in Patients With Colorectal Cancer Finding the Needle in the Haystack. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 308(15), 1581-1583.

Long-Term Survivors of Gastric Cancer: A California Population-Based Study
Kunz, P. L., Gubens, M., Fisher, G. A., Ford, J. M., Lichtensztajn, D. Y., & Clarke, C. A. (2012). Long-Term Survivors of Gastric Cancer: A California Population-Based Study. JOURNAL OF CLINICAL ONCOLOGY, 30(28), 3507-3515.

Genetic Testing by Cancer Site Stomach
Chun, N., & Ford, J. M. (2012). Genetic Testing by Cancer Site Stomach. CANCER JOURNAL, 18(4), 355-363.

Breast cancers with compromised DNA repair exhibit selective sensitivity to elesclomol
Alli, E., & Ford, J. M. (2012). Breast cancers with compromised DNA repair exhibit selective sensitivity to elesclomol. DNA REPAIR, 11(5), 522-524.

Is breast cancer a part of Lynch syndrome?
Ford, J. M. (2012). Is breast cancer a part of Lynch syndrome?. Breast cancer research : BCR, 14(4), 110.

Strategies to Identify the Lynch Syndrome Among Patients With Colorectal Cancer A Cost-Effectiveness Analysis
Ladabaum, U., Wang, G., Terdiman, J., Blanco, A., Kuppermann, M., & Phillips, K. A. (2011). Strategies to Identify the Lynch Syndrome Among Patients With Colorectal Cancer A Cost-Effectiveness Analysis. ANNALS OF INTERNAL MEDICINE, 155(2), 69-U50.

Enhanced sensitivity to cisplatin and gemcitabine in Brca1-deficient murine mammary epithelial cells.
Alli, E., Sharma, V. B., Hartman, A.-R., Lin, P. S., McPherson, L., & Ford, J. M. (2011). Enhanced sensitivity to cisplatin and gemcitabine in Brca1-deficient murine mammary epithelial cells. BMC pharmacology, 11, 7-?.

Synergistic Chemosensitivity of Triple-Negative Breast Cancer Cell Lines to Poly(ADP-Ribose) Polymerase Inhibition, Gemcitabine, and Cisplatin
Hastak, K., Alli, E., & Ford, J. M. (2010). Synergistic Chemosensitivity of Triple-Negative Breast Cancer Cell Lines to Poly(ADP-Ribose) Polymerase Inhibition, Gemcitabine, and Cisplatin. CANCER RESEARCH, 70(20), 7970-7980.

Second Primary Breast Cancer Occurrence According to Hormone Receptor Status
Kurian, A. W., McClure, L. A., John, E. M., Horn-Ross, P. L., Ford, J. M., & Clarke, C. A. (2009). Second Primary Breast Cancer Occurrence According to Hormone Receptor Status. JOURNAL OF THE NATIONAL CANCER INSTITUTE, 101(15), 1058-1065.

Defective Repair of Oxidative DNA Damage in Triple-Negative Breast Cancer Confers Sensitivity to Inhibition of Poly(ADP-Ribose) Polymerase
Alli, E., Sharma, V. B., Sunderesakumar, P., & Ford, J. M. (2009). Defective Repair of Oxidative DNA Damage in Triple-Negative Breast Cancer Confers Sensitivity to Inhibition of Poly(ADP-Ribose) Polymerase. CANCER RESEARCH, 69(8), 3589-3596.

Performance of BRCA1/2 mutation prediction models in Asian Americans
Kurian, A. W., Gong, G. D., Chun, N. M., Mills, M. A., Staton, A. D., & Ford, J. M. (2008). Performance of BRCA1/2 mutation prediction models in Asian Americans. JOURNAL OF CLINICAL ONCOLOGY, 26(29), 4752-4758.

Hereditary diffuse gastric cancer - Implications of genetic testing for screening and prophylactic surgery
Cisco, R. M., Ford, J. M., & Norton, J. A. (2008). Hereditary diffuse gastric cancer - Implications of genetic testing for screening and prophylactic surgery. CANCER, 113(7), 1850-1856.

CDH1 truncating mutations in the E-cadherin gene - An indication for total gastrectomy to treat hereditary diffuse gastric cancer
Norton, J. A., Ham, C. M., Van Dam, J., Jeffrey, R. B., Longacre, T. A., & Ford, J. M. (2007). CDH1 truncating mutations in the E-cadherin gene - An indication for total gastrectomy to treat hereditary diffuse gastric cancer. ANNALS OF SURGERY, 245(6), 873-879.

Predicting and preventing hereditary colorectal cancer
Ford, J. M., & Whittemore, A. S. (2006). Predicting and preventing hereditary colorectal cancer. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 296(12), 1521-1523.

Molecular inversion probe analysis of gene copy alterations reveals distinct categories of colorectal carcinoma
Ji, H., Kumm, J., Zhang, M., Farnam, K., Salari, K., & Davis, R. W. (2006). Molecular inversion probe analysis of gene copy alterations reveals distinct categories of colorectal carcinoma. CANCER RESEARCH, 66(16), 7910-7919.

Opposing effects of the UV lesion repair protein XPA and UV bypass polymerase eta on ATR checkpoint signaling
D Bomgarden, R., Lupardus, P. J., Soni, D. V., Yee, M.-C., Ford, J. M., & Cimprich, K. A. (2006). Opposing effects of the UV lesion repair protein XPA and UV bypass polymerase eta on ATR checkpoint signaling. EMBO JOURNAL, 25(11), 2605-2614.

In vivo recruitment of XPC to UV-induced cyclobutane pyrimidine dimers by the DDB2 gene product
Fitch, M. E., Nakajima, S., Yasui, A., & Ford, J. M. (2003). In vivo recruitment of XPC to UV-induced cyclobutane pyrimidine dimers by the DDB2 gene product. JOURNAL OF BIOLOGICAL CHEMISTRY, 278(47), 46906-46910.

p53 and regulation of DNA damage recognition during nucleotide excision repair
Adimoolam, S., & Ford, J. M. (2003). p53 and regulation of DNA damage recognition during nucleotide excision repair. DNA REPAIR, 2(9), 947-954.

The DDB2 nucleotide excision repair gene product p48 enhances global genomic repair in p53 deficient human fibroblasts
Fitch, M. E., Cross, I. V., Turner, S. J., Adimoolam, S., Lin, C. X., & Ford, J. A. (2003). The DDB2 nucleotide excision repair gene product p48 enhances global genomic repair in p53 deficient human fibroblasts. DNA REPAIR, 2(7), 819-826.

p53 responsive nucleotide excision repair gene products p48 and XPC, but not p53, localize to sites of UV-irradiation-induced DNA damage, in vivo
Fitch, M. E., Cross, I. V., & Ford, J. M. (2003). p53 responsive nucleotide excision repair gene products p48 and XPC, but not p53, localize to sites of UV-irradiation-induced DNA damage, in vivo. CARCINOGENESIS, 24(5), 843-850.

p53 and DNA damage-inducible expression of the xeroderma pigmentosum group C gene
Adimoolam, S., & Ford, J. M. (2002). p53 and DNA damage-inducible expression of the xeroderma pigmentosum group C gene. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 99(20), 12985-12990.

BRCA1 induces DNA damage recognition factors and enhances nucleotide excision repair
Hartman, A. R., & Ford, J. M. (2002). BRCA1 induces DNA damage recognition factors and enhances nucleotide excision repair. NATURE GENETICS, 32(1), 180-184.

Xeroderma pigmentosum p48 gene enhances global genomic repair and suppresses UV-induced mutagenesis
Tang, J. Y., Hwang, B. J., Ford, J. M., Hanawalt, P. C., & Chu, G. (2000). Xeroderma pigmentosum p48 gene enhances global genomic repair and suppresses UV-induced mutagenesis. MOLECULAR CELL, 5(4), 737-744.

Expression of the p48 xeroderma pigmentosum gene is p53-dependent and is involved in global genomic repair
Hwang, B. J., Ford, J. M., Hanawalt, P. C., & Chu, G. (1999). Expression of the p48 xeroderma pigmentosum gene is p53-dependent and is involved in global genomic repair. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 96(2), 424-428.

Expression of wild-type p53 is required for efficient global genomic nucleotide excision repair in UV-irradiated human fibroblasts
Ford, J. M., & Hanawalt, P. C. (1997). Expression of wild-type p53 is required for efficient global genomic nucleotide excision repair in UV-irradiated human fibroblasts. JOURNAL OF BIOLOGICAL CHEMISTRY, 272(44), 28073-28080.

LI-FRAUMENI SYNDROME FIBROBLASTS HOMOZYGOUS FOR P53 MUTATIONS ARE DEFICIENT IN GLOBAL DNA-REPAIR BUT EXHIBIT NORMAL TRANSCRIPTION-COUPLED REPAIR AND ENHANCED UV RESISTANCE
Ford, J. M., & Hanawalt, P. C. (1995). LI-FRAUMENI SYNDROME FIBROBLASTS HOMOZYGOUS FOR P53 MUTATIONS ARE DEFICIENT IN GLOBAL DNA-REPAIR BUT EXHIBIT NORMAL TRANSCRIPTION-COUPLED REPAIR AND ENHANCED UV RESISTANCE. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 92(19), 8876-8880.

The MLH1 c.-27C > A and c.85G > T variants are linked to dominantly inherited MLH1 epimutation and are borne on a European ancestral haplotype
Kwok, C.-T., Vogelaar, I. P., van Zelst-Stams, W. A., Mensenkamp, A. R., Ligtenberg, M. J., & Hitchins, M. P. (2014). The MLH1 c.-27C > A and c.85G > T variants are linked to dominantly inherited MLH1 epimutation and are borne on a European ancestral haplotype. EUROPEAN JOURNAL OF HUMAN GENETICS, 22(5), 617-624.

Clinical Interpretation and Implications of Whole-Genome Sequencing
Dewey, F. E., Grove, M. E., Pan, C., Goldstein, B. A., Bernstein, J. A., & Quertermous, T. (2014). Clinical Interpretation and Implications of Whole-Genome Sequencing. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 311(10), 1035-1044.

Parent decision-making around the genetic testing of children for germline TP53 mutations.
Alderfer, M. A., Zelley, K., Lindell, R. B., Novokmet, A., Mai, P. L., & Nichols, K. E. (2014). Parent decision-making around the genetic testing of children for germline TP53 mutations. Cancer.

Lynch syndrome screening should be considered for all patients with newly diagnosed endometrial cancer.
Mills, A. M., Liou, S., Ford, J. M., Berek, J. S., Pai, R. K., & Longacre, T. A. (2014). Lynch syndrome screening should be considered for all patients with newly diagnosed endometrial cancer. The American journal of surgical pathology, 38(11), 1501-9.

A clinical trial of lovastatin for modification of biomarkers associated with breast cancer risk
Vinayak, S., Schwartz, E. J., Jensen, K., Lipson, J., Alli, E., & Kurian, A. W. (2013). A clinical trial of lovastatin for modification of biomarkers associated with breast cancer risk. BREAST CANCER RESEARCH AND TREATMENT, 142(2), 389-398.

Dynamic contrast-enhanced MRI-based biomarkers of therapeutic response in triple-negative breast cancer
Golden, D. I., Lipson, J. A., Telli, M. L., Ford, J. M., & Rubin, D. L. (2013). Dynamic contrast-enhanced MRI-based biomarkers of therapeutic response in triple-negative breast cancer. JOURNAL OF THE AMERICAN MEDICAL INFORMATICS ASSOCIATION, 20(6), 1059-1066.

A Young Woman With Bilateral Breast Cancer: Identifying a Genetic Cause and Implications for Management
de Bruin, M. A., Ford, J. M., & Kurian, A. W. (2013). A Young Woman With Bilateral Breast Cancer: Identifying a Genetic Cause and Implications for Management. JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK, 11(5), 512-517.

Seventh Edition (2010) of the AJCC/UICC Staging System for Gastric Adenocarcinoma: Is there Room for Improvement?
Patel, M. I., Rhoads, K. F., Ma, Y., Ford, J. M., Visser, B. C., & Poultsides, G. A. (2013). Seventh Edition (2010) of the AJCC/UICC Staging System for Gastric Adenocarcinoma: Is there Room for Improvement?. ANNALS OF SURGICAL ONCOLOGY, 20(5), 1631-1638.

Breast cancer risk factors differ between Asian and white women with BRCA1/2 mutations
de Bruin, M. A., Kwong, A., Goldstein, B. A., Lipson, J. A., Ikeda, D. M., & Kurian, A. W. (2012). Breast cancer risk factors differ between Asian and white women with BRCA1/2 mutations. FAMILIAL CANCER, 11(3), 429-439.

Chest Wall Leiomyosarcoma After Breast-Conservative Therapy for Early-Stage Breast Cancer in a Young Woman With Li-Fraumeni Syndrome
Henry, E., Villalobos, V., Million, L., Jensen, K. C., West, R., & Telli, M. L. (2012). Chest Wall Leiomyosarcoma After Breast-Conservative Therapy for Early-Stage Breast Cancer in a Young Woman With Li-Fraumeni Syndrome. JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK, 10(8), 939-942.

Clinicopathologic and molecular features of sporadic early-onset colorectal adenocarcinoma: an adenocarcinoma with frequent signet ring cell differentiation, rectal and sigmoid involvement, and adverse morphologic features
Chang, D. T., Pai, R. K., Rybicki, L. A., DiMaio, M. A., Limaye, M., & Pai, R. K. (2012). Clinicopathologic and molecular features of sporadic early-onset colorectal adenocarcinoma: an adenocarcinoma with frequent signet ring cell differentiation, rectal and sigmoid involvement, and adverse morphologic features. MODERN PATHOLOGY, 25(8), 1128-1139.

Single Cell Profiling of Circulating Tumor Cells: Transcriptional Heterogeneity and Diversity from Breast Cancer Cell Lines
Powell, A. A., Talasaz, Aa. H., Zhang, H., Coram, M. A., Reddy, A., & Jeffrey, S. S. (2012). Single Cell Profiling of Circulating Tumor Cells: Transcriptional Heterogeneity and Diversity from Breast Cancer Cell Lines. PLOS ONE, 7(5).

Intensity-Modulated Radiotherapy for Pancreatic Adenocarcinoma
Abelson, J. A., Murphy, J. D., Minn, A. Y., Chung, M., Fisher, G. A., & Chang, D. T. (2012). Intensity-Modulated Radiotherapy for Pancreatic Adenocarcinoma. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 82(4), E595-E601.

Family History As a Positive Prognostic Factor in Gastric Cancer
Nadauld, L. D., & Ford, J. M. (2012). Family History As a Positive Prognostic Factor in Gastric Cancer. JOURNAL OF CLINICAL ONCOLOGY, 30(7), 683-684.

Identification of a Functional In Vivo p53 Response Element in the Coding Sequence of the Xeroderma Pigmentosum Group C Gene.
Hastak, K., Adimoolam, S., Trinklein, N. D., Myers, R. M., & Ford, J. M. (2012). Identification of a Functional In Vivo p53 Response Element in the Coding Sequence of the Xeroderma Pigmentosum Group C Gene. Genes & cancer, 3(2), 131-140.

Identification of a novel deletion mutant strain in Saccharomyces cerevisiae that results in a microsatellite instability phenotype.
Ji, H. P., Morales, S., Welch, K., Yuen, C., Farnam, K., & Ford, J. M. (2012). Identification of a novel deletion mutant strain in Saccharomyces cerevisiae that results in a microsatellite instability phenotype. BioDiscovery, (1).

HER2 Expression in Gastric and Gastroesophageal Junction Adenocarcinoma in a US Population: Clinicopathologic Analysis With Proposed Approach to HER2 Assessment
Kunz, P. L., Mojtahed, A., Fisher, G. A., Ford, J. M., Chang, D. T., & Pai, R. K. (2012). HER2 Expression in Gastric and Gastroesophageal Junction Adenocarcinoma in a US Population: Clinicopathologic Analysis With Proposed Approach to HER2 Assessment. APPLIED IMMUNOHISTOCHEMISTRY & MOLECULAR MORPHOLOGY, 20(1), 13-24.

A Prospective Study of Total Gastrectomy for CDH1-Positive Hereditary Diffuse Gastric Cancer
Chen, Y., Kingham, K., Ford, J. M., Rosing, J., Van Dam, J., & Norton, J. A. (2011). A Prospective Study of Total Gastrectomy for CDH1-Positive Hereditary Diffuse Gastric Cancer. ANNALS OF SURGICAL ONCOLOGY, 18(9), 2594-2598.

Intensity-Modulated Radiation Therapy Versus Conventional Radiation Therapy for Squamous Cell Carcinoma of the Anal Canal
Bazan, J. G., Hara, W., Hsu, A., Kunz, P. A., Ford, J., & Chang, D. T. (2011). Intensity-Modulated Radiation Therapy Versus Conventional Radiation Therapy for Squamous Cell Carcinoma of the Anal Canal. CANCER, 117(15), 3342-3351.

A two-antibody mismatch repair protein immunohistochemistry screening approach for colorectal carcinomas, skin sebaceous tumors, and gynecologic tract carcinomas
Mojtahed, A., Schrijver, I., Ford, J. M., Longacre, T. A., & Pai, R. K. (2011). A two-antibody mismatch repair protein immunohistochemistry screening approach for colorectal carcinomas, skin sebaceous tumors, and gynecologic tract carcinomas. MODERN PATHOLOGY, 24(7), 1004-1014.

Asian ethnicity and breast cancer subtypes: a study from the California Cancer Registry
Telli, M. L., Chang, E. T., Kurian, A. W., Keegan, T. Hm., McClure, L. A., & Gomez, S. L. (2011). Asian ethnicity and breast cancer subtypes: a study from the California Cancer Registry. BREAST CANCER RESEARCH AND TREATMENT, 127(2), 471-478.

Expression of p16(INK4A) But Not Hypoxia Markers or Poly Adenosine Diphosphate-Ribose Polymerase Is Associated With Improved Survival in Patients With Pancreatic Adenocarcinoma
Chang, D. T., Chapman, C. H., Norton, J. A., Visser, B., Fisher, G. A., & Pai, R. K. (2010). Expression of p16(INK4A) But Not Hypoxia Markers or Poly Adenosine Diphosphate-Ribose Polymerase Is Associated With Improved Survival in Patients With Pancreatic Adenocarcinoma. CANCER, 116(22), 5179-5187.

Poly(ADP-Ribose) Polymerase Inhibition: "Targeted" Therapy for Triple-Negative Breast Cancer
Anders, C. K., Winer, E. P., Ford, J. M., Dent, R., Silver, D. P., & Carey, L. A. (2010). Poly(ADP-Ribose) Polymerase Inhibition: "Targeted" Therapy for Triple-Negative Breast Cancer. CLINICAL CANCER RESEARCH, 16(19), 4702-4710.

PARP inhibitors in breast cancer.
Telli, M. L., & Ford, J. M. (2010). PARP inhibitors in breast cancer. Clinical advances in hematology & oncology : H&O, 8(9), 629-635.

Comparison of Intensity-Modulated Radiotherapy and 3-Dimensional Conformal Radiotherapy as Adjuvant Therapy for Gastric Cancer
Minn, A. Y., Hsu, A., La, T., Kunz, P., Fisher, G. A., & Chang, D. T. (2010). Comparison of Intensity-Modulated Radiotherapy and 3-Dimensional Conformal Radiotherapy as Adjuvant Therapy for Gastric Cancer. CANCER, 116(16), 3943-3952.

(18)FLUORODEOXYGLUCOSE PET IS PROGNOSTIC OF PROGRESSION-FREE AND OVERALL SURVIVAL IN LOCALLY ADVANCED PANCREAS CANCER TREATED WITH STEREOTACTIC RADIOTHERAPY
Schellenberg, D., Quon, A., Minn, A. Y., Graves, E. E., Kunz, P., & Chang, D. T. (2010). (18)FLUORODEOXYGLUCOSE PET IS PROGNOSTIC OF PROGRESSION-FREE AND OVERALL SURVIVAL IN LOCALLY ADVANCED PANCREAS CANCER TREATED WITH STEREOTACTIC RADIOTHERAPY. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 77(5), 1420-1425.

Hereditary diffuse gastric cancer due to a previously undescribed CDH1 splice site mutation
Matsukuma, K. E., Mullins, F. M., Dietz, L., Zehnder, J. L., Ford, J. M., & Schrijver, I. (2010). Hereditary diffuse gastric cancer due to a previously undescribed CDH1 splice site mutation. HUMAN PATHOLOGY, 41(8), 1200-1203.

Pathological response after chemoradiation for T3 rectal cancer
Chennupati, S. K., Kamaya, A., Fisher, G. A., Ford, J. M., Kunz, P., & Chang, D. T. (2010). Pathological response after chemoradiation for T3 rectal cancer. COLORECTAL DISEASE, 12(7), E24-E30.

Pathological response after chemoradiation for T3 rectal cancer.
Chennupati, S. K., Kamaya, A., Fisher, G. A., Ford, J. M., Kunz, P., & Chang, D. T. (2010). Pathological response after chemoradiation for T3 rectal cancer. Colorectal disease , 12(7 Online), e24-30.

Novel Treatment Approaches for Triple-Negative Breast Cancer
Telli, M. L., & Ford, J. M. (2010). Novel Treatment Approaches for Triple-Negative Breast Cancer. CLINICAL BREAST CANCER, 10, E16-E22.

Longer Relative Telomere Length in Blood from Women with Sporadic and Familial Breast Cancer Compared with Healthy Controls
Gramatges, M. M., Telli, M. L., Balise, R., & Ford, J. M. (2010). Longer Relative Telomere Length in Blood from Women with Sporadic and Familial Breast Cancer Compared with Healthy Controls. CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION, 19(2), 605-613.

Oncogenic BRAF Mutation with CDKN2A Inactivation Is Characteristic of a Subset of Pediatric Malignant Astrocytomas
Schiffman, J. D., Hodgson, J. G., VandenBerg, S. R., Flaherty, P., Polley, M.-Y. C., & James, C. D. (2010). Oncogenic BRAF Mutation with CDKN2A Inactivation Is Characteristic of a Subset of Pediatric Malignant Astrocytomas. CANCER RESEARCH, 70(2), 512-519.

PARP Inhibitors for the Treatment and Prevention of Breast Cancer.
Vinayak, S., & Ford, J. M. (2010). PARP Inhibitors for the Treatment and Prevention of Breast Cancer. Current breast cancer reports, 2(4), 190-197.

Multimodality treatment with intensity modulated radiation therapy for esophageal cancer
La, T. H., Minn, A. Y., Su, Z., Fisher, G. A., Ford, J. M., & Chang, D. T. (2010). Multimodality treatment with intensity modulated radiation therapy for esophageal cancer. DISEASES OF THE ESOPHAGUS, 23(4), 300-308.

Identification of a biomarker panel using a multiplex proximity ligation assay improves accuracy of pancreatic cancer diagnosis
Chang, S. T., Zahn, J. M., Horecka, J., Kunz, P. L., Ford, J. M., & Koong, A. C. (2009). Identification of a biomarker panel using a multiplex proximity ligation assay improves accuracy of pancreatic cancer diagnosis. JOURNAL OF TRANSLATIONAL MEDICINE, 7.

A BRCA2 founder mutation and seven novel deleterious BRCA mutations in southern Chinese women with breast and ovarian cancer
Kwong, A., Wong, L. P., Wong, H. N., Law, F. Bf., Ng, E. Ko., & Ford, J. M. (2009). A BRCA2 founder mutation and seven novel deleterious BRCA mutations in southern Chinese women with breast and ovarian cancer. BREAST CANCER RESEARCH AND TREATMENT, 117(3), 683-686.

The role of the retinoblastoma/E2F1 tumor suppressor pathway in the lesion recognition step of nucleotide excision repair
Lin, P. S., McPherson, L. A., Chen, A. Y., Sage, J., & Ford, J. M. (2009). The role of the retinoblastoma/E2F1 tumor suppressor pathway in the lesion recognition step of nucleotide excision repair. DNA REPAIR, 8(7), 795-802.

Detection of Solitary Humeral Metastasis From Pancreatic Adenocarcinoma With F-18 FDG PET/CT
Kim, J., Quon, A., Humke, E., Ford, J. M., & Koong, A. C. (2009). Detection of Solitary Humeral Metastasis From Pancreatic Adenocarcinoma With F-18 FDG PET/CT. CLINICAL NUCLEAR MEDICINE, 34(5), 312-313.

Stereotactic Radiotherapy for Unresectable Adenocarcinoma of the Pancreas
Chang, D. T., Schellenberg, D., Shen, J., Kim, J., Goodman, K. A., & Koong, A. C. (2009). Stereotactic Radiotherapy for Unresectable Adenocarcinoma of the Pancreas. CANCER, 115(3), 665-672.

Gemcitabine chemotherapy and single-fraction stereotactic body radiotherapy for locally advanced pancreatic cancer
Schellenberg, D., Goodman, K. A., Lee, F., Chang, S., Kuo, T., & Koong, A. C. (2008). Gemcitabine chemotherapy and single-fraction stereotactic body radiotherapy for locally advanced pancreatic cancer. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 72(3), 678-686.

Microsatellite instability and mismatch repair protein defects in ovarian epithelial neoplasms in patients 50 years of age and younger
Jensen, K. C., Mariappan, M. R., Putcha, G. V., Husain, A., Chun, N., & Longacre, T. A. (2008). Microsatellite instability and mismatch repair protein defects in ovarian epithelial neoplasms in patients 50 years of age and younger. AMERICAN JOURNAL OF SURGICAL PATHOLOGY, 32(7), 1029-1037.

Cancer risk reduction and reproductive concerns in female BRCA1/2 mutation carriers
Staton, A. D., Kurian, A. W., Cobb, K., Mills, M. A., & Ford, J. M. (2008). Cancer risk reduction and reproductive concerns in female BRCA1/2 mutation carriers. FAMILIAL CANCER, 7(2), 179-186.

Risk-reducing total gastrectomy for germline mutations in E-cadherin (CDH1): Pathologic findings with clinical implications
Rogers, W. M., Dobo, E., Norton, J. A., Van Dam, J., Jeffrey, R. B., & Longacre, T. A. (2008). Risk-reducing total gastrectomy for germline mutations in E-cadherin (CDH1): Pathologic findings with clinical implications. AMERICAN JOURNAL OF SURGICAL PATHOLOGY, 32A(6), 799-809.

Characterization of the pathogenic mechanism of a novel BRCA2 variant in a Chinese family
Kwong, A., Wong, L. P., Chan, K. Yk., Ma, E. Sk., Khoo, U. S., & Ford, J. M. (2008). Characterization of the pathogenic mechanism of a novel BRCA2 variant in a Chinese family. FAMILIAL CANCER, 7(2), 125-133.

Identification of a novel p53 in-frame deletion in a Li-Fraumeni-like family
Schiffman, J. D., Chun, N., Fisher, P. G., Dahl, G. V., Ford, J. M., & Eggerding, F. A. (2008). Identification of a novel p53 in-frame deletion in a Li-Fraumeni-like family. PEDIATRIC BLOOD & CANCER, 50(4), 914-916.

Magnetic resonance galactography: A feasibility study in women with prior atypical breast duct cytology
Kurian, A. W., Hartman, A.-R., Mills, M. A., Logan, L. J., Sawyer, A. M., & Daniel, B. L. (2008). Magnetic resonance galactography: A feasibility study in women with prior atypical breast duct cytology. BREAST JOURNAL, 14(2), 211-214.

HDAC inhibitor PCI-24781 decreases RAD51 expression and inhibits homologous recombination
Adimoolam, S., Sirisawad, M., Chen, J., Thiemann, P., Ford, J. M., & Buggy, J. J. (2007). HDAC inhibitor PCI-24781 decreases RAD51 expression and inhibits homologous recombination. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 104(49), 19482-19487.

A carrier of both MEN1 and BRCA2 mutations: case report a-lid review of the literature
Ghataorhe, P., Kurian, A. W., Pickart, A., Trapane, P., Norton, J. A., & Ford, J. M. (2007). A carrier of both MEN1 and BRCA2 mutations: case report a-lid review of the literature. CANCER GENETICS AND CYTOGENETICS, 179(2), 89-92.

Identification of an intronic single nucleotide polymorphism leading to allele dropout during validation of a CDH1 sequencing assay: implications for designing polymerase chain reaction-based assays
Mullins, F. M., Dietz, L., Lay, M., Zehnder, J. L., Ford, J., & Schrijver, I. (2007). Identification of an intronic single nucleotide polymorphism leading to allele dropout during validation of a CDH1 sequencing assay: implications for designing polymerase chain reaction-based assays. GENETICS IN MEDICINE, 9(11), 752-760.

Founder and recurrent CDH1 mutations in families with hereditary diffuse gastric cancer
Kaurah, P., MacMillan, A., Boyd, N., Senz, J., De Luca, A., & Huntsman, D. (2007). Founder and recurrent CDH1 mutations in families with hereditary diffuse gastric cancer. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 297(21), 2360-2372.

Ductal pattern enhancement on magnetic resonance imaging of the breast due to ductal lavage
Ghanouni, P., Kurian, A. W., Margolis, D., Hartman, A.-R., Mills, M. A., & Daniel, B. L. (2007). Ductal pattern enhancement on magnetic resonance imaging of the breast due to ductal lavage. BREAST JOURNAL, 13(3), 281-286.

Reversal of stathmin-mediated resistance to paclitaxel and vinblastine in human breast carcinoma cells
Alli, E., Yang, J.-M., Ford, J. M., & Hait, W. N. (2007). Reversal of stathmin-mediated resistance to paclitaxel and vinblastine in human breast carcinoma cells. MOLECULAR PHARMACOLOGY, 71(5), 1233-1240.

Germ line mutations of mismatch repair genes in hereditary nonpolyposis colorectal cancer patients with small bowel cancer: International Society for Gastrointestinal Hereditary Tumours Collaborative Study
Park, J.-G., Kim, D.-W., Hong, C. W., Nam, B.- ho, Shin, Y.-K., & Wijnen, J. (2006). Germ line mutations of mismatch repair genes in hereditary nonpolyposis colorectal cancer patients with small bowel cancer: International Society for Gastrointestinal Hereditary Tumours Collaborative Study. CLINICAL CANCER RESEARCH, 12(11), 3389-3393.

A kinase-independent function of c-Abl in promoting proteolytic destruction of damaged DNA binding proteins
Chen, X., Zhang, J., Lee, J., Lin, P. S., Ford, J. M., & Zhou, P. (2006). A kinase-independent function of c-Abl in promoting proteolytic destruction of damaged DNA binding proteins. MOLECULAR CELL, 22(4), 489-499.

Colorectal Cancer Screening Clinical Practice Guidelines.
Levin, B., Barthel, J. S., Burt, R. W., David, D. S., Ford, J. M., & Winawer, S. J. (2006). Colorectal Cancer Screening Clinical Practice Guidelines. Journal of the National Comprehensive Cancer Network , 4(4), 384-420.

Genetic/familial high-risk assessment: breast and ovarian.
Daly, M. B., Axilbund, J. E., Bryant, E., Buys, S., Eng, C., & Weitzel, J. N. (2006). Genetic/familial high-risk assessment: breast and ovarian. Journal of the National Comprehensive Cancer Network , 4(2), 156-176.

Phase II study to assess the efficacy of conventionally fractionated radiotherapy followed by a stereotactic radiosurgery boost in patients with locally advanced pancreatic cancer
Koong, A. C., Christofferson, E., Le, Q. T., Goodman, K. A., Ho, A., & Yang, G. P. (2005). Phase II study to assess the efficacy of conventionally fractionated radiotherapy followed by a stereotactic radiosurgery boost in patients with locally advanced pancreatic cancer. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 63(2), 320-323.

Regulation of DNA damage recognition and nucleotide excision repair: Another role for p53
Ford, J. M. (2005). Regulation of DNA damage recognition and nucleotide excision repair: Another role for p53. MUTATION RESEARCH-FUNDAMENTAL AND MOLECULAR MECHANISMS OF MUTAGENESIS, 577(1-2), 195-202.

Opinions of women with high inherited breast cancer risk about prophylactic mastectomy: an initial evaluation from a screening trial including magnetic resonance imaging and ductal lavage
Kurian, A. W., Hartman, A. R., Mills, M. A., Ford, J. M., Daniel, B. L., & Plevritis, S. K. (2005). Opinions of women with high inherited breast cancer risk about prophylactic mastectomy: an initial evaluation from a screening trial including magnetic resonance imaging and ductal lavage. HEALTH EXPECTATIONS, 8(3), 221-233.

Phase II study of gefitinib, fluorouracil, leucovorin, and oxaliplatin therapy in previously treated patients with metastatic colorectal cancer
Kuo, T., Cho, C. D., Halsey, J., Wakelee, H. A., Advani, R. H., & Sikic, B. I. (2005). Phase II study of gefitinib, fluorouracil, leucovorin, and oxaliplatin therapy in previously treated patients with metastatic colorectal cancer. JOURNAL OF CLINICAL ONCOLOGY, 23(24), 5613-5619.

Characterization of a recurrent germ line mutation of the E-cadherin gene: Implications for genetic testing and clinical management
Suriano, G., Yew, S., Ferreira, P., Senz, J., Kaurah, P., & Huntsman, D. G. (2005). Characterization of a recurrent germ line mutation of the E-cadherin gene: Implications for genetic testing and clinical management. CLINICAL CANCER RESEARCH, 11(15), 5401-5409.

Ductal lavage of fluid-yielding and non-fluid-yielding ducts in BRCA1 and BRCA2 mutation carriers and other women at high inherited breast cancer risk
Kurian, A. W., Mills, M. A., Jaffee, M., Sigal, B. M., Chun, N. M., & Hartman, A. R. (2005). Ductal lavage of fluid-yielding and non-fluid-yielding ducts in BRCA1 and BRCA2 mutation carriers and other women at high inherited breast cancer risk. CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION, 14(5), 1082-1089.

Phase I study of stereotactic radiosurgery in patients with locally advanced pancreatic cancer
Koong, A. C., Le, Q. T., Ho, A., Fong, B., Fisher, G., & Bastidas, J. A. (2004). Phase I study of stereotactic radiosurgery in patients with locally advanced pancreatic cancer. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 58(4), 1017-1021.

Breast magnetic resonance image screening and ductal lavage in women at high genetic risk for breast carcinoma
Hartman, A. R., Daniel, B. L., Kurian, A. W., Mills, M. A., Nowels, K. W., & Plevritis, S. K. (2004). Breast magnetic resonance image screening and ductal lavage in women at high genetic risk for breast carcinoma. CANCER, 100(3), 479-489.

Functional characterization of global genomic DNA repair and its implications for cancer
Hanawalt, P. C., Ford, J. A., & Lloyd, D. R. (2003). Functional characterization of global genomic DNA repair and its implications for cancer. MUTATION RESEARCH-REVIEWS IN MUTATION RESEARCH, 544(2-3), 107-114.

BRCA1 and p53: compensatory roles in DNA repair
Hartman, A. R., & Ford, J. M. (2003). BRCA1 and p53: compensatory roles in DNA repair. JOURNAL OF MOLECULAR MEDICINE-JMM, 81(11), 700-707.

Defective double-strand DNA break repair and chromosomal translocations by MYC overexpression
Karlsson, A., Deb-Basu, D., Cherry, A., Turner, S., Ford, J., & Felsher, D. W. (2003). Defective double-strand DNA break repair and chromosomal translocations by MYC overexpression. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 100(17), 9974-9979.

Phase II trial of preoperative 3D conformal radiotherapy, protracted venous infusion 5-fluorouracil, and weekly CPT-11, followed by surgery for ultrasound-staged T3 rectal cancer
Mehta, V. K., Cho, C., Ford, J. M., Jambalos, C., Poen, J., & Fisher, G. (2003). Phase II trial of preoperative 3D conformal radiotherapy, protracted venous infusion 5-fluorouracil, and weekly CPT-11, followed by surgery for ultrasound-staged T3 rectal cancer. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 55(1), 132-137.

DNA Damage, Repair, and Diseases.
Wiesmüller, L., Ford, J. M., & Schiestl, R. H. (2002). DNA Damage, Repair, and Diseases. Journal of biomedicine & biotechnology, 2(2), 45.

The p53-regulated cyclin-dependent kinase inhibitor, p21 (cip1, waf1, sdi1), is not required for global genomic and transcription-coupled nucleotide excision repair of UV-induced DNA photoproducts
Adimoolam, S., Lin, C. X., & Ford, J. M. (2001). The p53-regulated cyclin-dependent kinase inhibitor, p21 (cip1, waf1, sdi1), is not required for global genomic and transcription-coupled nucleotide excision repair of UV-induced DNA photoproducts. JOURNAL OF BIOLOGICAL CHEMISTRY, 276(28), 25813-25822.

Protracted venous infusion 5-fluorouracil with concomitant radiotherapy compared with bolus 5-fluorouracil for unresectable pancreatic cancer
Mehta, V. K., Poen, J. C., Ford, J. M., Oberhelman, H. A., Vierra, M. A., & Fisher, G. A. (2001). Protracted venous infusion 5-fluorouracil with concomitant radiotherapy compared with bolus 5-fluorouracil for unresectable pancreatic cancer. AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS, 24(2), 155-159.

Radiotherapy, concomitant protracted-venous-infusion 5-fluorouracil, and surgery for ultrasound-staged T3 or T4 rectal cancer
Mehta, V. K., Poen, J., Ford, J., Edelstein, P. S., Vierra, M., & Fisher, G. (2001). Radiotherapy, concomitant protracted-venous-infusion 5-fluorouracil, and surgery for ultrasound-staged T3 or T4 rectal cancer. DISEASES OF THE COLON & RECTUM, 44(1), 52-58.

Preoperative chemoradiation for marginally resectable adenocarcinoma of the pancreas
Mehta, V. K., Fisher, G., Ford, J. A., Poen, J. C., Vierra, M. A., & Bastidas, J. A. (2001). Preoperative chemoradiation for marginally resectable adenocarcinoma of the pancreas. JOURNAL OF GASTROINTESTINAL SURGERY, 5(1), 27-35.

Adjuvant chemoradiotherapy for "unfavorable" carcinoma of the ampulla of vater - Preliminary report
Mehta, V. K., Fisher, G. A., Ford, J. M., Poen, J. C., Vierra, M. A., & Bastidas, A. J. (2001). Adjuvant chemoradiotherapy for "unfavorable" carcinoma of the ampulla of vater - Preliminary report. ARCHIVES OF SURGERY, 136(1), 65-69.

Adjuvant radiotherapy and concomitant 5-fluorouracil by protracted venous infusion for resected pancreatic cancer
Mehta, V. K., Fisher, G. A., Ford, J. M., Oberhelman, H. A., Vierra, M. A., & Poen, J. C. (2000). Adjuvant radiotherapy and concomitant 5-fluorouracil by protracted venous infusion for resected pancreatic cancer. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 48(5), 1483-1487.

Proapoptotic p53-interacting protein 53BP2 is induced by UV irradiation but suppressed by p53
Lopez, C. D., Ao, Y., Rohde, L. H., Perez, T. D., O'Connor, D. J., & Naumovski, L. (2000). Proapoptotic p53-interacting protein 53BP2 is induced by UV irradiation but suppressed by p53. MOLECULAR AND CELLULAR BIOLOGY, 20(21), 8018-8025.

Reduced global genomic repair of ultraviolet light-induced cyclobutane pyrimidine dimers in simian virus 40-transformed human cells
Bowman, K. K., Sicard, D. M., Ford, J. M., & Hanawalt, P. C. (2000). Reduced global genomic repair of ultraviolet light-induced cyclobutane pyrimidine dimers in simian virus 40-transformed human cells. MOLECULAR CARCINOGENESIS, 29(1), 17-24.

Decreased UV sensitivity, mismatch repair activity and abnormal cell cycle checkpoints in skin cancer cell lines derived from UVB-irradiated XPA-deficient mice
Ichikawa, M., Nakane, H., Marra, G., Corti, C., Jiricny, J., & Tanaka, K. (2000). Decreased UV sensitivity, mismatch repair activity and abnormal cell cycle checkpoints in skin cancer cell lines derived from UVB-irradiated XPA-deficient mice. MUTATION RESEARCH-DNA REPAIR, 459(4), 285-298.

p53-mediated DNA repair responses to UV radiation: Studies of mouse cells lacking p53, p21, and/or gadd45 genes
Smith, M. L., Ford, J. M., Hollander, M. C., Bortnick, R. A., Amundson, S. A., & Fornace, A. J. (2000). p53-mediated DNA repair responses to UV radiation: Studies of mouse cells lacking p53, p21, and/or gadd45 genes. MOLECULAR AND CELLULAR BIOLOGY, 20(10), 3705-3714.

Chemoradiotherapy in the management of localized tumors of the pancreas
Poen, J. C., Ford, J. M., & Niederhuber, J. E. (1999). Chemoradiotherapy in the management of localized tumors of the pancreas. ANNALS OF SURGICAL ONCOLOGY, 6(1), 117-122.

Hepatitis B x protein inhibits p53-dependent DNA repair in primary mouse hepatocytes
Prost, S., Ford, J. M., Taylor, G., Doig, J., & Harrison, D. J. (1998). Hepatitis B x protein inhibits p53-dependent DNA repair in primary mouse hepatocytes. JOURNAL OF BIOLOGICAL CHEMISTRY, 273(50), 33327-33332.

Human fibroblasts expressing the human papillomavirus E6 gene are deficient in global genomic nucleotide excision repair and sensitive to ultraviolet irradiation
Ford, J. M., Baron, E. L., & Hanawalt, P. C. (1998). Human fibroblasts expressing the human papillomavirus E6 gene are deficient in global genomic nucleotide excision repair and sensitive to ultraviolet irradiation. CANCER RESEARCH, 58(4), 599-603.

Role of DNA excision repair gene defects in the etiology of cancer
Ford, J. M., & Hanawalt, P. C. (1997). Role of DNA excision repair gene defects in the etiology of cancer. GENETIC INSTABILITY AND TUMORIGENESIS, 221, 47-70.

Experimental reversal of P-glycoprotein-mediated multidrug resistance by pharmacological chemosensitisers
Ford, J. M. (1996). Experimental reversal of P-glycoprotein-mediated multidrug resistance by pharmacological chemosensitisers. EUROPEAN JOURNAL OF CANCER, 32A(6), 991-1001.

P-glycoprotein-mediated multidrug resistance: experimental and clinical strategies for its reversal.
Ford, J. M., Yang, J. M., & Hait, W. N. (1996). P-glycoprotein-mediated multidrug resistance: experimental and clinical strategies for its reversal. Cancer treatment and research, 87, 3-38.

MODULATORS OF MULTIDRUG-RESISTANCE - PRECLINICAL STUDIES
Ford, J. M. (1995). MODULATORS OF MULTIDRUG-RESISTANCE - PRECLINICAL STUDIES. HEMATOLOGY-ONCOLOGY CLINICS OF NORTH AMERICA, 9(2), 337-361.

PREFERENTIAL REPAIR OF ULTRAVIOLET LIGHT-INDUCED DNA-DAMAGE IN THE TRANSCRIBED STRAND OF THE HUMAN P53 GENE
Ford, J. M., Lommel, L., & Hanawalt, P. C. (1994). PREFERENTIAL REPAIR OF ULTRAVIOLET LIGHT-INDUCED DNA-DAMAGE IN THE TRANSCRIBED STRAND OF THE HUMAN P53 GENE. MOLECULAR CARCINOGENESIS, 10(2), 105-109.

PHARMACOLOGICAL CIRCUMVENTION OF MULTIDRUG-RESISTANCE
Ford, J. M., & Hait, W. N. (1993). PHARMACOLOGICAL CIRCUMVENTION OF MULTIDRUG-RESISTANCE. CYTOTECHNOLOGY, 12(1-3), 171-212.

EFFECT OF BUTHIONINE SULFOXIMINE ON TOXICITY OF VERAPAMIL AND DOXORUBICIN TO MULTIDRUG RESISTANT CELLS AND TO MICE
Ford, J. M., Yang, J. M., & Hait, W. N. (1991). EFFECT OF BUTHIONINE SULFOXIMINE ON TOXICITY OF VERAPAMIL AND DOXORUBICIN TO MULTIDRUG RESISTANT CELLS AND TO MICE. CANCER RESEARCH, 51(1), 67-72.

MODULATION OF RESISTANCE TO ALKYLATING-AGENTS IN CANCER CELL BY GOSSYPOL ENANTIOMERS
Ford, J. M., Hait, W. N., Matlin, S. A., & Benz, C. C. (1991). MODULATION OF RESISTANCE TO ALKYLATING-AGENTS IN CANCER CELL BY GOSSYPOL ENANTIOMERS. CANCER LETTERS, 56(1), 85-94.

PHARMACOLOGY OF DRUGS THAT ALTER MULTIDRUG RESISTANCE IN CANCER
Ford, J. M., & Hait, W. N. (1990). PHARMACOLOGY OF DRUGS THAT ALTER MULTIDRUG RESISTANCE IN CANCER. PHARMACOLOGICAL REVIEWS, 42(3), 155-199.

BIOCHEMICAL CORRELATES OF THE ANTITUMOR AND ANTIMITOCHONDRIAL PROPERTIES OF GOSSYPOL ENANTIOMERS
Benz, C. C., Keniry, M. A., Ford, J. M., Townsend, A. J., COX, F. W., & COWAN, K. H. (1990). BIOCHEMICAL CORRELATES OF THE ANTITUMOR AND ANTIMITOCHONDRIAL PROPERTIES OF GOSSYPOL ENANTIOMERS. MOLECULAR PHARMACOLOGY, 37(6), 840-847.

CELLULAR AND BIOCHEMICAL-CHARACTERIZATION OF THIOXANTHENES FOR REVERSAL OF MULTIDRUG RESISTANCE IN HUMAN AND MURINE CELL-LINES
Ford, J. M., Bruggemann, E. P., Pastan, I., Gottesman, M. M., & Hait, W. N. (1990). CELLULAR AND BIOCHEMICAL-CHARACTERIZATION OF THIOXANTHENES FOR REVERSAL OF MULTIDRUG RESISTANCE IN HUMAN AND MURINE CELL-LINES. CANCER RESEARCH, 50(6), 1748-1756.

TOREMIFENE - PHARMACOLOGIC AND PHARMACOKINETIC BASIS OF REVERSING MULTIDRUG RESISTANCE
DeGregorio, M. W., Ford, J. M., Benz, C. C., & Wiebe, V. J. (1989). TOREMIFENE - PHARMACOLOGIC AND PHARMACOKINETIC BASIS OF REVERSING MULTIDRUG RESISTANCE. JOURNAL OF CLINICAL ONCOLOGY, 7(9), 1359-1364.

STRUCTURAL FEATURES DETERMINING ACTIVITY OF PHENOTHIAZINES AND RELATED DRUGS FOR INHIBITION OF CELL-GROWTH AND REVERSAL OF MULTIDRUG RESISTANCE
Ford, J. M., Prozialeck, W. C., & Hait, W. N. (1989). STRUCTURAL FEATURES DETERMINING ACTIVITY OF PHENOTHIAZINES AND RELATED DRUGS FOR INHIBITION OF CELL-GROWTH AND REVERSAL OF MULTIDRUG RESISTANCE. MOLECULAR PHARMACOLOGY, 35(1), 105-115.